January 2025 in “JCEM Case Reports” Ketoconazole improved symptoms of ACTH-independent Cushing syndrome despite inconclusive initial scans.
Testosterone pellet therapy may better address hormone imbalances in aging by focusing on local hormone production and symptom relief.
50 citations
,
April 2000 in “Fertility and Sterility” Diane 35 plus finasteride is more effective in reducing hair growth and androgen levels, but may decrease libido.
December 2025 in “Fertility and Sterility” Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
30 citations
,
August 2010 in “American Journal of Clinical Dermatology” Cetuximab can cause eyelash growth, which is rare but manageable.
January 2026 in “Frontiers in Pharmacology” Cedrol may help treat inflammatory bowel disease by improving gut health and function.
14 citations
,
February 1994 in “Tetrahedron Letters” Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
15 citations
,
November 1983 in “British journal of dermatology/British journal of dermatology, Supplement” Testosterone increases hamster hair growth; cyproterone acetate reduces it.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
1 citations
,
September 2024 in “Journal of Clinical & Translational Endocrinology” PCOS women have more severe metabolic issues and higher androgen levels than hyperandrogenic women without PCOS.
9 citations
,
May 2021 in “Molecules” New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.
April 2023 in “Journal of Investigative Dermatology” CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.
September 2023 in “Journal of the American Academy of Dermatology” Obese children respond worse to CARP treatment than non-obese children.
April 2020 in “Research Square (Research Square)” Oral contraceptives with cyproterone acetate improved quality of life for women with PCOS more than those with levonorgestrel.
September 2024 in “Uro-Technology Journal”
January 1987 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Norethisterone (jenapharm) therapy is effective for endometrial cancer.
May 2018 in “Más dermatología” The higher dose supplement was more effective in treating female hair loss.
January 2026 in “Nature Reviews Urology”
41 citations
,
December 2008 in “Current Opinion in Ophthalmology” Certain eye surgery complications can be managed effectively, especially in patients who have used specific prostate medications.
24 citations
,
May 1951 in “Endocrinology” Adrenocorticotropic hormone inhibits growth and affects body composition in male rats.
1 citations
,
December 2025 in “Baylor University Medical Center Proceedings” Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.
12 citations
,
January 1993 in “PubMed”
October 2024 in “Journal of the Endocrine Society” Surgical removal of a rare ovarian tumor improved symptoms and hormone levels in a postmenopausal woman.
2 citations
,
January 2023 in “Dermatologic Therapy” CEFFE injections effectively and safely improve postinflammatory hyperpigmentation.
41 citations
,
April 1997 in “Fertility and sterility” Clomiphene citrate can reverse low hormone levels and symptoms in male runners with hypogonadotropic hypogonadism.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
December 2024 in “Reactions Weekly” December 2023 in “Reactions weekly”